Home
CORT
CORT News

Latest Corcept Therapeutics Incorporated (CORT) News on January 22, 2025

Here’s Why Analysts Are Bullish on Corcept Therapeutics Incorporated (CORT)

Insider Monkey

a day ago

Here’s Why Analysts Are Bullish on Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Incorporated (CORT): Why Should You Buy This Growth Stock For The Next 5 Years?

Insider Monkey

4 days ago

Corcept Therapeutics Incorporated (CORT): Why Should You Buy This Growth Stock For The Next 5 Years?

Argus Research

7 days ago

CORT: What does Argus have to say about CORT?

Discover 3 US Growth Stocks With Strong Insider Ownership

Simply Wall St.

15 days ago

Discover 3 US Growth Stocks With Strong Insider Ownership

Corcept Therapeutics Incorporated (CORT) Surged on Strong Results and Increased Guidance

Insider Monkey

15 days ago

Corcept Therapeutics Incorporated (CORT) Surged on Strong Results and Increased Guidance

Corcept Submits Application for Another Cushing's Syndrome Drug

Zacks

22 days ago

Corcept Submits Application for Another Cushing's Syndrome Drug

MT Newswires

23 days ago

Corcept Therapeutics Files New Drug Application for Relacorilant

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

Business Wire

23 days ago

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

Will Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025?

Insider Monkey

a month ago

Will Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025?

Argus Research

a month ago

CORT: Lowering target price to $53.00

Argus Research

a month ago

CORT: Lowering target price to $58.00

Corcept Therapeutics’ Cushing’s syndrome therapy shows promise in Phase III trial

Clinical Trials Arena

a month ago

Corcept Therapeutics’ Cushing’s syndrome therapy shows promise in Phase III trial

MT Newswires

a month ago

Corcept Therapeutics' Phase 3 Study of Relacorilant Shows Improvements in Patients With Hypercortisolism

Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

Business Wire

a month ago

Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes

Benzinga

a month ago

Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes

MT Newswires

a month ago

Corcept Therapeutics Phase 4 Trial of Korlym Shows Hemoglobin A1c Reduction in Patients With Hypercortisolism, Diabetes

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes

Business Wire

a month ago

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes

CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study

Zacks

a month ago

CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study

MT Newswires

a month ago

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday

MT Newswires

a month ago

Corcept Phase 2 Trial of Dazucorilant for Amyotrophic Lateral Sclerosis Fails to Meet Primary Endpoint

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

Business Wire

a month ago

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating

Investor's Business Daily

a month ago

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating

Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock

Zacks

a month ago

Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock

Argus Research

a month ago

CORT: Lowering target price to $62.00

Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why

Zacks

a month ago

Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why

Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound?

Zacks

2 months ago

Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound?

Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High?

Zacks

2 months ago

Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High?

3 US Stocks With High Insider Ownership And Up To 79% Growth

Simply Wall St.

2 months ago

3 US Stocks With High Insider Ownership And Up To 79% Growth

Zoetis (ZTS) Up 1% Since Last Earnings Report: Can It Continue?

Zacks

2 months ago

Zoetis (ZTS) Up 1% Since Last Earnings Report: Can It Continue?

Argus Research

2 months ago

CORT: Raising target price to $63.00

Corcept Therapeutics (NASDAQ:CORT) shareholders have earned a 34% CAGR over the last five years

Simply Wall St.

2 months ago

Corcept Therapeutics (NASDAQ:CORT) shareholders have earned a 34% CAGR over the last five years

Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue?

Zacks

2 months ago

Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue?

Argus Research

2 months ago

CORT: Rating decreased to a HOLD

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

Zacks

2 months ago

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

Corcept Shares Rise More Than 60% in Three Months: Here's Why

Zacks

2 months ago

Corcept Shares Rise More Than 60% in Three Months: Here's Why

3 Reasons Growth Investors Will Love Corcept (CORT)

Zacks

2 months ago

3 Reasons Growth Investors Will Love Corcept (CORT)

Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet

Zacks

2 months ago

Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet

Argus Research

2 months ago

CORT: Rating decreased to a HOLD

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

Zacks

2 months ago

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

5 Small Drug Stocks to Buy as Trump Gets Re-Elected

Zacks

2 months ago

5 Small Drug Stocks to Buy as Trump Gets Re-Elected

5 Stocks With Recent Price Strength to Tap Wall Street Rally

Zacks

2 months ago

5 Stocks With Recent Price Strength to Tap Wall Street Rally

Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue?

Zacks

2 months ago

Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue?

Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy?

Zacks

3 months ago

Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy?

3 US Growth Stocks With Insider Ownership As High As 37%

Simply Wall St.

3 months ago

3 US Growth Stocks With Insider Ownership As High As 37%

Argus Research

3 months ago

CORT: Rating increased to a BUY

Here is Why Growth Investors Should Buy Corcept (CORT) Now

Zacks

3 months ago

Here is Why Growth Investors Should Buy Corcept (CORT) Now

Corcept (CORT) Upgraded to Strong Buy: Here's Why

Zacks

3 months ago

Corcept (CORT) Upgraded to Strong Buy: Here's Why

Best Momentum Stocks to Buy for November 5th

Zacks

3 months ago

Best Momentum Stocks to Buy for November 5th

Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out?

Zacks

3 months ago

Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out?

Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade

Zacks

3 months ago

Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

3 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy?

Zacks

3 months ago

Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy?

Corcept’s relacorilant GRADIENT trial misses primary endpoint

Clinical Trials Arena

3 months ago

Corcept’s relacorilant GRADIENT trial misses primary endpoint

Corcept Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

3 months ago

Corcept Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View

Zacks

3 months ago

Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View

Corcept Therapeutics Inc (CORT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com

3 months ago

Corcept Therapeutics Inc (CORT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates

Zacks

3 months ago

Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates

Associated Press Finance

3 months ago

Corcept: Q3 Earnings Snapshot

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update

Business Wire

3 months ago

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Business Wire

3 months ago

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Buy Low-Beta Stocks JD, SKWD, CORT, PRA to Beat Election Uncertainty

Zacks

3 months ago

Buy Low-Beta Stocks JD, SKWD, CORT, PRA to Beat Election Uncertainty

Zacks.com featured highlights Idaho Strategic, Qifu, Sezzle, Corcept and FinWise

Zacks

3 months ago

Zacks.com featured highlights Idaho Strategic, Qifu, Sezzle, Corcept and FinWise

5 Stocks With Recent Price Strength to Tap Wall Street Rally

Zacks

3 months ago

5 Stocks With Recent Price Strength to Tap Wall Street Rally

Strength Seen in Corcept (CORT): Can Its 5.5% Jump Turn into More Strength?

Zacks

3 months ago

Strength Seen in Corcept (CORT): Can Its 5.5% Jump Turn into More Strength?

Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High?

Zacks

3 months ago

Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High?

Implied Volatility Surging for Corcept Therapeutics (CORT) Stock Options

Zacks

3 months ago

Implied Volatility Surging for Corcept Therapeutics (CORT) Stock Options

Zacks.com featured highlights include Atour Lifestyle, Vertiv, Corcept Therapeutics, Qifu Technology and ADMA Biologics

Zacks

3 months ago

Zacks.com featured highlights include Atour Lifestyle, Vertiv, Corcept Therapeutics, Qifu Technology and ADMA Biologics

5 Stocks With Recent Price Strength Amid October Volatility

Zacks

3 months ago

5 Stocks With Recent Price Strength Amid October Volatility

Zacks.com featured highlights include Corcept Therapeutics, Abercrombie & Fitch and HCI Group

Zacks

3 months ago

Zacks.com featured highlights include Corcept Therapeutics, Abercrombie & Fitch and HCI Group

3 Strong Buy Momentum Stocks as Bull Market Nears 2-Year Mark

Zacks

3 months ago

3 Strong Buy Momentum Stocks as Bull Market Nears 2-Year Mark

Argus Research

3 months ago

CORT: Lowering target price to $48.00

3 US Growth Stocks With Insider Ownership And 20% Revenue Growth

Simply Wall St.

3 months ago

3 US Growth Stocks With Insider Ownership And 20% Revenue Growth

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Is Going Strong: Is the Market Following Fundamentals?

Simply Wall St.

3 months ago

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Is Going Strong: Is the Market Following Fundamentals?

MT Newswires

4 months ago

Corcept Therapeutics Insider Sold Shares Worth $462,800, According to a Recent SEC Filing

Wall Street Analysts Think Corcept (CORT) Could Surge 41.31%: Read This Before Placing a Bet

Zacks

4 months ago

Wall Street Analysts Think Corcept (CORT) Could Surge 41.31%: Read This Before Placing a Bet

Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?

Zacks

4 months ago

Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast

Benzinga

4 months ago

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast

MT Newswires

4 months ago

Truist Raises Price Target on Corcept Therapeutics to $76 From $65, Keeps Buy Rating

Does Corcept Therapeutics (CORT) Have a Long Runway for Growth?

Insider Monkey

4 months ago

Does Corcept Therapeutics (CORT) Have a Long Runway for Growth?

Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?

Zacks

4 months ago

Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?

Do Options Traders Know Something About Corcept (CORT) Stock We Don't?

Zacks

4 months ago

Do Options Traders Know Something About Corcept (CORT) Stock We Don't?

US Growth Companies With High Insider Ownership

Simply Wall St.

4 months ago

US Growth Companies With High Insider Ownership

Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report?

Zacks

5 months ago

Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report?

Here's Why Corcept Therapeutics (NASDAQ:CORT) Has Caught The Eye Of Investors

Simply Wall St.

5 months ago

Here's Why Corcept Therapeutics (NASDAQ:CORT) Has Caught The Eye Of Investors

Corcept Shares Rise More Than 45% in Six Months: Here's Why

Zacks

5 months ago

Corcept Shares Rise More Than 45% in Six Months: Here's Why

Corcept (CORT) Down 4% Since Last Earnings Report: Can It Rebound?

Zacks

5 months ago

Corcept (CORT) Down 4% Since Last Earnings Report: Can It Rebound?

Argus Research

5 months ago

CORT: What does Argus have to say about CORT?

Corcept (CORT) Upgraded to Buy: Here's Why

Zacks

5 months ago

Corcept (CORT) Upgraded to Buy: Here's Why

Argus Research

5 months ago

CORT: Raising target price to $36.00

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia

Zacks

5 months ago

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia

Wall Street Analysts Believe Corcept (CORT) Could Rally 70.58%: Here's is How to Trade

Zacks

5 months ago

Wall Street Analysts Believe Corcept (CORT) Could Rally 70.58%: Here's is How to Trade

5 Small Drug Stocks to Buy as Innovation Reaches Peak

Zacks

5 months ago

5 Small Drug Stocks to Buy as Innovation Reaches Peak

3 US Growth Companies With High Insider Ownership

Simply Wall St.

5 months ago

3 US Growth Companies With High Insider Ownership

Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?

Zacks

6 months ago

Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?

Can Corcept (CORT) Run Higher on Rising Earnings Estimates?

Zacks

6 months ago

Can Corcept (CORT) Run Higher on Rising Earnings Estimates?

Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice

Zacks

6 months ago

Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice

Wall Street Analysts See a 37.6% Upside in Corcept (CORT): Can the Stock Really Move This High?

Zacks

6 months ago

Wall Street Analysts See a 37.6% Upside in Corcept (CORT): Can the Stock Really Move This High?

Corcept Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

6 months ago

Corcept Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates

Zacks

6 months ago

Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates

Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates

Zacks

6 months ago

Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates

Share on Social Networks: